Skip to content
Film Television Auditions – Lifestyle
Author:
Cosmos Health Inc.
Cosmos Health Reports Q1 2026 Results: Revenue Up 31% to $17.9M, New Q1 Record; Total Liabilities Reduced by $4.5M; Stockholders’ Equity Up 7.6%; Cash of $2.2M; Record Momentum Continues into Q2 with U.S. Expansion Underway
May 21, 2026
Cosmos Health, through its Subsidiary Cana Laboratories, Enters into an Advisory Agreement with the European Investment Bank (EIB) for the Financing of its €50M R&D Program; EIB Financing Represents up to 50%, or €25M, under the EIB’s Venture Debt Program
May 14, 2026
Cosmos Health Announces Withdrawal of Registration Statement on Form S-1
May 12, 2026
Cosmos Health Receives Updated Zacks Research Report: 2026 Revenue Forecast Raised to $103.2 Million, EPS Outlook Upgraded to Positive Territory, and $4.50 Valuation Reaffirmed
May 8, 2026
Cosmos Health Introduces Fort18 in the United States – A Men’s Sexual Stamina Supplement Expanding the 18 Series into Men’s Wellness
May 7, 2026
Cosmos Health Projects Over $2.5 Million in Incremental Annual Revenue from Cur18 in the United States Within 12-18 Months
April 30, 2026
←
Previous Page
1
…
5
6
7